# Tenmile

> Tenmile is a VC fund in Perth backing Health Care, Biotechnology and Manufacturing. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Perth, Australia
- Total investments: 20
- Last investment: Jul 2026
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/tenmile
- Website: https://www.tenmile.com

Tenmile is a VC fund in Perth focused on Health Care and Biotechnology. Tenmile invest quickly and confidently because it lacks the constraints that most venture capital funds.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $7M–$8M |
| Series A | $3M–$177M |
| Venture - Series Unknown | $7.5M–$90M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 45% |
| Biotechnology | 9 | 45% |
| Manufacturing | 4 | 20% |
| Pharmaceutical | 3 | 15% |
| Medical | 2 | 10% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 7 | 35% |
| Series A | 4 | 20% |
| Seed | 2 | 10% |
| Series B | 2 | 10% |
| Series C | 1 | 5% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Australia | 9 | 45% |
| United States | 7 | 35% |
| Canada | 1 | 5% |
| Switzerland | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M | Series D | Jul 15, 2026 |  |
| Syndeio Biosciences | Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders. | $90M | Venture - Series Unknown | May 27, 2025 |  |
| Antares Therapeutics | Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M | Series A | May 15, 2025 |  |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M | Series C | Feb 03, 2025 |  |
| Proton Intelligence | Proton Intelligence provides biomarker monitoring to manage chronic disease and save lives. The first biomarker is potassium, targeting hyperkalemia in chronic kidney disease (CKD) patients who have additional co-morbidities ProtonIntel was founded in 2020 and was headquartered in Vancouver, Canada. | $7M | Seed | Dec 24, 2024 |  |
| Xylo Bio | Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications. | $8M | Seed | Jun 02, 2024 |  |
| Stamford Pharmaceuticals | Stamford Pharmaceuticals delivers biologicals, small molecule immune modulators, and chemotherapeutics to treat cancer patients. |  | Series A | Apr 10, 2024 |  |
| LimmaTech Biologics | LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $3M | Series A | Feb 01, 2024 |  |
| Revagenix | Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. |  | Series B | Jan 05, 2024 |  |
| Revagenix | Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. |  | Series B | Jan 05, 2024 |  |

10 of 20 investments shown.

## Co-investors
- [Repair Impact Fund](https://shizune.co/investors/profile/repair-impact-fund) — VC Fund, 5 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 4 deals together
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 3 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 2 deals together
- [M8 Ventures](https://shizune.co/investors/profile/m8-ventures) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Australia](https://shizune.co/investors/biotechnology-investors-australia)
- [Biotechnology VC Funds in Australia](https://shizune.co/investors/biotechnology-vc-funds-australia)
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)
- [Wellness Investors in Australia](https://shizune.co/investors/wellness-investors-australia)
- [Wellness VC Funds in Australia](https://shizune.co/investors/wellness-vc-funds-australia)

## FAQ

### What does Tenmile invest in?

Tenmile invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Venture - Series Unknown and Series A stage. Most of the 20 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Tenmile's check size?

Tenmile typically joins rounds of $7M–$8M at Seed, $3M–$177M at Series A and $7.5M–$90M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Tenmile participates in.

### When did Tenmile last invest?

The most recent investment recorded for Tenmile closed in Jul 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co